Neuregulin-4 (human) (rec.)
Human Neuregulin-4 (aa 1-53) is fused at the N-terminus to GST.
Binds to the human receptor tyrosine-protein kinase ErbB4.
|Endotoxin Content||<0.01EU/μg purified protein (LAL test).|
|Concentration||0.1mg/ml after reconstitution.|
|Reconstitution||Reconstitute with 100μl sterile water.|
|Formulation||Lyophilized. Contains PBS.|
|Other Product Data||
UniProt link Q8WWG1: Neuregulin-4 (human)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Neuregulin-4 (Nrg4) belongs to a small family of EGF-like (EGFL) domain-containing proteins that are synthesized as transmembrane precursors and undergo proteolytic cleavage. The EGF-like domain (aa 5-46) of Nrg4 (aa 1-53) directly binds to the receptors ErbB3 and 4. Nrg4 is a cold induced adipokine, highly expressed in adipose tissues and enriched in brown fat. It is increased during brown adipocyte differentiation and reduced in rodent and human obesity. It promotes neurite outgrowth and protects against diet-induced insulin resistance and hepatic steatosis through attenuating hepatic lipogenic signaling. This hepatic effect of Nrg4 is mediated by ErbB3 and ErbB4 signaling that negatively regulates de novo lipogenesis mediated by LXR and SREBP1c. This effect of Nrg4 on fatty liver and insulin resistance could lead to the development of Nrg4 as an effective therapeutic biological for the treatment of NAFLD and type 2 diabetes. GST-Nrg4 (aa 1-53) recombinant protein has been shown to mimic the effect of endogenous secreted Nrg4 on liver lipogenesis.